State of play of pharmacogenetics and personalized medicine in heart failure

Helen M. Parry; Alexander Doney; Colin N. A. Palmer; Chim C. Lang

doi:10.1111/1755-5922.12030

State of play of pharmacogenetics and personalized medicine in heart failure

Helen M. Parry (Lead / Corresponding author), Alexander Doney, Colin N. A. Palmer, Chim C. Lang

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Heart failure is a common disease with high levels of morbidity and mortality. A large body of evidence guiding treatment shows prognostic benefit with beta blockers and ACE inhibitors, while diuretics are commonly prescribed for symptomatic benefit. Wide variation in drug response between clinically similar patients is a significant problem. Evidence suggests this may have a genetic component. © 2013 Blackwell Publishing Ltd.

Original language	English
Pages (from-to)	315-322
Number of pages	8
Journal	Cardiovascular Therapeutics
Volume	31
Issue number	6
DOIs	https://doi.org/10.1111/1755-5922.12030
Publication status	Published - 2013

Access to Document

10.1111/1755-5922.12030

Health Informatics Centre
Health and Clinical Services
Facility/equipment: Facility

Cite this

@article{99f6fe73b08d43f8b362ac9ee24c737f,

title = "State of play of pharmacogenetics and personalized medicine in heart failure",

abstract = "Heart failure is a common disease with high levels of morbidity and mortality. A large body of evidence guiding treatment shows prognostic benefit with beta blockers and ACE inhibitors, while diuretics are commonly prescribed for symptomatic benefit. Wide variation in drug response between clinically similar patients is a significant problem. Evidence suggests this may have a genetic component. {\textcopyright} 2013 Blackwell Publishing Ltd.",

author = "Parry, {Helen M.} and Alexander Doney and Palmer, {Colin N. A.} and Lang, {Chim C.}",

note = "{\textcopyright} 2013 Blackwell Publishing Ltd.",

year = "2013",

doi = "10.1111/1755-5922.12030",

language = "English",

volume = "31",

pages = "315--322",

journal = "Cardiovascular Therapeutics",

issn = "1755-5922",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - State of play of pharmacogenetics and personalized medicine in heart failure

AU - Parry, Helen M.

AU - Doney, Alexander

AU - Palmer, Colin N. A.

AU - Lang, Chim C.

PY - 2013

Y1 - 2013

N2 - Heart failure is a common disease with high levels of morbidity and mortality. A large body of evidence guiding treatment shows prognostic benefit with beta blockers and ACE inhibitors, while diuretics are commonly prescribed for symptomatic benefit. Wide variation in drug response between clinically similar patients is a significant problem. Evidence suggests this may have a genetic component. © 2013 Blackwell Publishing Ltd.

AB - Heart failure is a common disease with high levels of morbidity and mortality. A large body of evidence guiding treatment shows prognostic benefit with beta blockers and ACE inhibitors, while diuretics are commonly prescribed for symptomatic benefit. Wide variation in drug response between clinically similar patients is a significant problem. Evidence suggests this may have a genetic component. © 2013 Blackwell Publishing Ltd.

U2 - 10.1111/1755-5922.12030

DO - 10.1111/1755-5922.12030

M3 - Article

C2 - 23480579

SN - 1755-5922

VL - 31

SP - 315

EP - 322

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

IS - 6

ER -

State of play of pharmacogenetics and personalized medicine in heart failure

Abstract

Access to Document

Fingerprint

Equipment

Health Informatics Centre

Cite this